Asset Details
Do you wish to reserve the book?
Nucleoside-modified VEGFC mRNA induces organ-specific lymphatic growth and reverses experimental lymphedema
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Nucleoside-modified VEGFC mRNA induces organ-specific lymphatic growth and reverses experimental lymphedema
Do you wish to request the book?
Nucleoside-modified VEGFC mRNA induces organ-specific lymphatic growth and reverses experimental lymphedema
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Nucleoside-modified VEGFC mRNA induces organ-specific lymphatic growth and reverses experimental lymphedema
2021
Overview
Lack or dysfunction of the lymphatics leads to secondary lymphedema formation that seriously reduces the function of the affected organs and results in degradation of quality of life. Currently, there is no definitive treatment option for lymphedema. Here, we utilized nucleoside-modified mRNA encapsulated in lipid nanoparticles (LNPs) encoding murine Vascular Endothelial Growth Factor C (VEGFC) to stimulate lymphatic growth and function and reduce experimental lymphedema in mouse models. We demonstrated that administration of a single low-dose of VEGFC mRNA-LNPs induced durable, organ-specific lymphatic growth and formation of a functional lymphatic network. Importantly, VEGFC mRNA-LNP treatment reversed experimental lymphedema by restoring lymphatic function without inducing any obvious adverse events. Collectively, we present a novel application of the nucleoside-modified mRNA-LNP platform, describe a model for identifying the organ-specific physiological and pathophysiological roles of the lymphatics, and propose an efficient and safe treatment option that may serve as a novel therapeutic tool to reduce lymphedema.
Dysfunction of the lymphatic system leads to secondary lymphedema and results in degradation of quality of life. Here, the authors show that delivery of nucleoside-modified Vascular Endothelial Growth Factor C (VEGFC) mRNA, encapsulated in lipid nanoparticles, induces organ-specific lymphatic growth and reverses experimental lymphedema.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 13/106
/ 13/109
/ 13/31
/ 13/51
/ 14/1
/ 14/34
/ 14/35
/ 14/63
/ 38/1
/ 38/109
/ 38/35
/ 38/77
/ 38/90
/ 38/91
/ 45/77
/ 64/110
/ 64/60
/ 82/1
/ 82/29
/ 82/51
/ 82/80
/ Animals
/ Cell Proliferation - drug effects
/ Diphtheria Toxin - pharmacology
/ Dosage
/ Humanities and Social Sciences
/ Humans
/ Lipids
/ Lipids - administration & dosage
/ Lymphangiogenesis - genetics
/ Lymphatic Vessels - drug effects
/ Lymphatic Vessels - pathology
/ Mice
/ mRNA
/ Nanoparticles - administration & dosage
/ Organs
/ Science
/ Vascular endothelial growth factor
/ Vascular endothelial growth factor C
/ Vascular Endothelial Growth Factor C - administration & dosage
We currently cannot retrieve any items related to this title. Kindly check back at a later time.